MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

9785-CL-0123

Protocol Title

A Phase 2 Open-Label Extension Study for Subjects with Prostate Cancer who Previously Participated in An Enzalutamide Clinical Study

A5481008 TRIO22

A Randomized, Multicenter, Double-Blind Phase 3 Study of PD-0332991 (Oral CDK 4/6 Inhibitor) plus Letrozole versus Placebo plus Letrozole for the Treatment of Postmenopausal Women with ER (+), HER2 (-) Breast Cancer who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced Disease

A5481023 PALOMA3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (Faslodex(R)) With or Without PD-0332991 (Palbociclib) Goserelin in Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy

AB154CSP0001

A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants with Advanced Malignancies

ACT001-AU-004

A Phase 2, Open Label, Multicentre Study Assessing the Safety and Efficacy of ACT001 in Combination with Whole Brain Radiation Therapy (WBRT) for Brain Metastases from Solid Tumours

AK104-101

A Phase 1A/1B Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects with Advanced Solid Tumours

AK104-201-AU

A Single-Arm, Open-Label, Global, Multicenter, Phase 2 Study to Evaluate the Efficacy of AK104 in Patients with Recurrent or Metastatic Cervical Cancer

AK104-201-AU

A Phase 2, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects with Recurrent or Metastatic Cervical Cancer

AK105-101

A Phase 1A/1B Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects with Advanced Solid Tumours

AK105-101

A Phase 1A/1B Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects with Advanced Solid Tumours